MedInCell Stock Climbs 4% to €27.06, Targeting Resistance at €28.72
The biotech company from Montpellier gains 4% to €27.06 by midday, ranking among the top risers on the SBF 120. The stock is nearing its resistance at €28.72 and maintains over 72% growth over one year. The rebound occurs in a rising Parisian market, with the SBF 120 up 0.68% during the session.
A Rebound Propels MedInCell Among the Top Gainers on the SBF 120
MedInCell ranks among the top risers on the SBF 120 at midday, alongside technology stocks such as Soitec (+8.98%), Exail Technologies (+7.84%), and STMicroelectronics (+5.12%). The stock has moved back above the €27 threshold after two sessions of consolidation. The movement is part of a well-oriented Parisian market context, with the CAC 40 up by 0.7% and the SBF 120 gaining 0.68% during the session. The bullish momentum remains strong over the long term: the stock retains a 72.8% gain over one year and 12.56% over three months, despite a weekly decline of 1.89%. Declared short positions indicate continued caution around the stock. Three funds together hold 2.07% of the capital in a net short position, a limited increase of 0.11 points over thirty days. This progression does not reflect a massive movement of distrust, but it indicates that some institutional investors remain positioned against the stock or are looking to cover exposure. This point should be monitored, though not interpreted in isolation.
The Stock Approaches Its Resistance at €28.72 After Crossing Its Moving Averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price is now above its three reference moving averages. The MM20 (€25.59), the MM50 (€23.59), and the MM200 (€24.79) have all been crossed, with a gap of 5.74% above the MM20 and 14.71% above the MM50. The RSI at 54 remains in the neutral zone, without an overbought configuration. The next graphical threshold is at €28.72, about 6% above the current price, a level that had already hindered the stock in May. The financial calendar provides a clear horizon for investors. The next expected publication concerns the annual results for the April 2025 - March 2026 fiscal year, scheduled for June 16, 2026. The 2026 general meeting is then set for September 10, followed by the semi-annual results on December 8. The shareholder structure, communicated in May 2026, shows 35.1% held by insiders and 31.9% by institutional investors, among them SmallCap World Fund (2.3%). The June 16 meeting will be the next major information point for the Montpellier biotech.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
